-
Benedé-Ubieto R, Estévez-Vázquez O, Acar R, Leal-Lassalle H, Gutierrez AH, Redondo-Urzainqui A, Iborra S, Odintsova VE, Tyakht A, Herranz JM, Firat Z, Basol M, Korkmaz B, Sanz-García C, Juanola O, Caparrós E, Francés R, Ciudin A, Pericàs JM, Gómez-Santos B, Aspichueta P, Treichel N, Clavel T, Reißing J, Bruns T, Bartneck M, Mazariegos MS, Wolters JC, Jorquera G, Liedtke C, Vaquero J, Bañares R, Cakan-Akdogan G, Ávila MA, Konu O, Cubero FJ, Nevzorova YA.
Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation.
Gut Microbes.,
2026
-
Heras JL, Suarez MU, Mercado-Gómez M, Gracianteparaluceta LU, Buqué X, Alonso C, Serrano-Macia M, Alcalde C, Cano A, González-Recio I, Goikoetxea-Usandizaga N, Mora E, Belanger-Quintana A, Cañedo-Villarroya E, Ceberio L, Chumillas-Calzada S, Correcher P, García-Arenas D, Gómez I, Hernández T, Izquierdo-García E, Chicano DM, Morales M, Pedrón-Giner C, Jáuregui EP, Peña-Quintana L, Sánchez-Pintos P, Serrano-Nieto J, Serrano-Gonzalo I, Miñana IV, Larena JA, Couce ML, Martínez-Chantar ML, Aspichueta P, Delgado TC.
Lipidomics uncovers metabolic manifestations related to liver steatosis and low-grade systemic inflammation in diet-treated hereditary fructose intolerance patients.
Clin Nutr.,
2026
-
Markaide E, Izquierdo-Sanchez L, Olaizola I, Urretabizkaia-Garmendia J, Ruiz de Gauna M, Buqué X, Lasa-Elosegi I, Lapitz A, Bais T, Val B, Rodrigues PM, Castro RE, Perugorria MJ, Bujanda L, Gansevoort R, Drenth JPH, Aspichueta P, Banales JM.
Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes.
Hepatology.,
2026
-
Banales JM, Rodrigues PM, Affò S, Andersen JB, Aspichueta P, Boulter L, Bridgewater J, Calvisi DF, Cardenas A, Cardinale V, Carpino G, Coulouarn C, Dopazo C, Edeline J, Fabris L, Folseraas T, Forner A, Goeppert B, Heikenwalder M, Kendall TJ, Khan SA, Klümpen HJ, Koerkamp BG, Lamarca A, Lindsey S, Lleo A, Luedde T, Macias RIR, Morement H, Nault JC, Olaizola P, Perugorria MJ, Raggi C, Rimassa L, Saborowski A, Valle JW, Vithayathil M, Vogel A, Braconi C; International CCA Consensus Consortium.
Cholangiocarcinoma 2026: status quo, unmet needs and priorities.
Nat Rev Gastroenterol Hepatol.,
2026
-
Nasir AB, Zouridis S, Aspichueta P, Manka P, Syn WK.
Relationship between depression and chronic liver disease: Potential role of antidepressants in modulating liver fibrosis.
Am J Med Sci.,
2025
-
Olaizola P, Olaizola I, Fernandez de Ara M, Lapitz A, Val B, Izquierdo-Sanchez L, Fernandez-Barrena MG, Alvarez L, O'Rourke CJ, Lee-Law PY, Davies K, Gradinaru A, Jimenez-Agüero R, La Casta A, Riaño I, Macias RIR, Marin JJG, Martinez-Chantar ML, Avila MA, Aspichueta P, Andersen JB, Boulter L, Bujanda L, Rodrigues PM, Perugorria MJ, Banales JM.
Targeting protein hyper-SUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma cross talk.
Hepatology.,
2025
-
Apodaka-Biguri M, Simão AL, González-Romero F, Mestre D, Rodrigues PM, Aurrekoetxea I, Gómez-Santos B, Buqué X, Nieva-Zuluaga A, de Gauna MR, Fernandez-Puertas I, Gomez-Jauregui P, Sainz-Ramirez N, Alfaro-Jiménez K, Ortiz-Palma A, Castillero E, Iglesias-Ara A, Mitxelena J, Eriz A, Aransay AM, Lozano JJ, Marin JJG, Izquierdo-Sanchez L, Perugorria MJ, Bujanda L, Banales JM, Martín C, Mosteiro L, Errazti G, Syn WK, Castaño L, Zubiaga AM, Castro RE, Aspichueta P.
E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.
Hepatology.,
2025
-
Albóniga OE, Cubiella J, Bujanda L, Aspichueta P, Blanco ME, Lanza B, Alonso C, Falcón-Pérez JM.
Metabolic Signature in Combination with Fecal Immunochemical Test as a Non-Invasive Tool for Advanced Colorectal Neoplasia Diagnosis.
Cancers (Basel).,
2025
-
Alloza-Moral I, Aldekoa-Etxabe A, Tulloch-Navarro R, Fiat-Arriola A, Mar C, Urrechaga E, Ponga C, Artiga-Folch I, Garcia-Bediaga N, Aspichueta P, Martin C, Zarandona-Garai A, Pérez-Fernández S, Arana-Arri E, Triviño JC, Uranga A, España PP, Vandenbroeck-van-Caeckenbergh K.
Genetic Analysis and Predictive Modeling of COVID-19 Severity in a Hospital-Based Patient Cohort.
Biomolecules.,
2025
-
Cicuéndez B, Mora A, López JA, Curtabbi A, Pérez-García J, Porteiro B, Jimenez-Blasco D, Latorre-Muro P, Vo P, Jerome M, Gómez-Santos B, Romero-Becerra R, Leiva M, Rodríguez E, León M, Leiva-Vega L, Gómez-Lado N, Torres JL, Hernández-Cosido L, Aguiar P, Marcos M, Jastroch M, Daiber A, Aspichueta P, Bolaños JP, Spinelli JB, Puigserver P, Enriquez JA, Vázquez J, Folgueira C, Sabio G.
Absence of MCJ/DnaJC15 promotes brown adipose tissue thermogenesis.
Nat Commun.,
2025
-
Saliba-Gustafsson P, Justesen JM, Ranta A, Sharma D, Bielczyk-Maczynska E, Li J, Najmi LA, Apodaka M, Aspichueta P, Björck HM, Eriksson P, Schurr TM, Franco-Cereceda A, Gloudemans M, Mujica E, den Hoed M, Assimes TL, Quertermous T, Carcamo-Orive I, Park CY, Knowles JW.
A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes
Hepatology.,
2024
-
Coombes JD, Manka PP, Swiderska-Syn M, Vannan DT, Riva A, Claridge LC, Moylan C, Suzuki A, Briones-Orta MA, Younis R, Kitamura N, Sydor S, Bittencourt S, Mi Z, Kuo PC, Diehl AM, van Grunsven LA, Chokshi S, Canbay A, Abdelmalek MF, Aspichueta P, Papa S, Eksteen B, Syn WK
Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASH
Liver Int.,
2024
-
Lamas-Paz A, Hionides-Gutiérrez A, Guo F, Jorquera G, Morán-Blanco L, Benedé-Ubieto R, Mesquita M, Estévez-Vázquez O, Zheng K, Mazariegos M, Vázquez-Ogando E, Blázquez-López E, Asensio I, Mutlu B, Gomez-Santos B, Peligros MI, Vaquero J, Bañares R, Delgado TC, Martínez-Chantar ML, Martínez-Naves E, Sanz-García C, Mohamed MR, Tesolato S, Iniesta P, Gallego-Durán R, Maya-Miles D, Ampuero J, Romero-Gómez M, Martínez-Alcocer A, Sanfeliu-Redondo D, Fernández-Iglesias A, Gracia-Sancho J, Coll M, Graupera I, Ginès P, Ciudin A, Rivera-Esteban J, Pericàs JM, Ávila MA, Frutos MD, Martínez-Cáceres CM, Ramos-Molina B, Aspichueta P, Puigserver P, Nevzorova YA, Cubero FJ.
Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis
JHEP Rep.,
2024
-
Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, Castro RE, Lapitz A, Izquierdo-Sanchez L, Bujanda L, Perugorria MJ, Banales JM, Rodrigues PM.
Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
Atherosclerosis,
2024
-
Zouridis S, Nasir AB, Aspichueta P, Syn WK.
The Link between Metabolic Syndrome and the Brain
Digestion,
2024
-
Rada P, Carceller-López E, Hitos AB, Gómez-Santos B, Fernández-Hernández C, Rey E, Pose-Utrilla J, García-Monzón C, González-Rodríguez Á, Sabio G, García A, Aspichueta P, Iglesias T, Valverde ÁM.
Protein kinase D2 modulates hepatic insulin sensitivity in male mice
Mol Metab.,
2024
-
Valdecantos MP, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M, Hitos AB, Field J, Francisco V, Escalona-Garrido C, Zagmutt S, Calderon-Dominguez M, Mera P, Garcia-Martinez I, Maymó-Masip E, Grajales D, Alen R, Mora A, Sáinz N, Vides-Urrestarazu I, Vilarrasa N, Arbones-Mainar JM, Zaragoza C, Moreno-Aliaga MJ, Aspichueta P, Fernández-Veledo S, Vendrell J, Serra D, Herrero L, Schreiber R, Zechner R, Sabio G, Hornigold D, Rondinone CM, Jermutus L, Grimsby J, Valverde ÁM.
The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk
Nat Commun.,
2024
-
Schmitt L, Krings KS, Wolsing A, Buque X, Zimmermann M, Flores-Romero H, Lenz T, Lechtenberg I, Peter C, Stork B, Teusch N, Proksch P, Stühler K, García-Sáez AJ, Reichert AS, Aspichueta P, Bhatia S, Wesselborg S.
Targeting mitochondrial metabolism by the mitotoxin bromoxib in leukemia and lymphoma cells
Cell Commun Signal.,
2024
-
Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Maya-Miles D, Diago M, Poca M, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Hernández-Guerra M, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Turnes J, Romero-Gómez M; HEPAmet Registry.
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
J Gastroenterol.,
2024
-
Noureddin M, Truong E, Mayo R, Martínez-Arranz I, Mincholé I, Banales JM, Arrese M, Cusi K, Arias-Loste MT, Bruha R, Romero-Gómez M, Iruzubieta P, Aller R, Ampuero J, Calleja JL, Ibañez-Samaniego L, Aspichueta P, Martín-Duce A, Kushner T, Ortiz P, Harrison SA, Anstee QM, Crespo J, Mato JM, Sanyal AJ.
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Hepatology.,
2024
